? Admedus to present world first aortic valve repair data using CardioCel® at the 29th European Association for Cardio-Thoracic Surgery Annual Meeting
? CardioCel® Tri-leaflet Aortic Valve Repair (CTRS) Clinical Study is scheduled to begin shortly Brisbane, Australia 10 September, 2015
Admedus Limited (ASX: AHZ) has today announced that it will present CardioCel® data for the complete repair of aortic heart valves at the 29th European Association for Cardio-Thoracic Surgery Annual Meeting (EACTS), which is being held in the Netherlands from 3 October to 7 October 2015.
The CardioCel session titled “AVR: What is new?”, will take place at EACTS on Monday, 5 October at 10.15am and will provide the full results of a pre-clinical trial undertaken by heart surgeon and lead researcher Professor Bart Meuris at KU Leuven University in Belgium.
“This study represents a world first tri-leaflet aortic valve repair in this animal model, and as a surgeon the results have been very exciting. I look forward to presenting the full findings at EACTS in October,” said Professor Bart Meuris, KU Leuven University.
The data presented at the EACTS conference will support the hundreds of patients that have already had their heart valve repaired with CardioCel.
“Demonstrating CardioCel’s success in this world first heart valve repair study is a key step for the Company, as we continue to develop personalised medical solutions with large market applications,” said Admedus CEO, Mr Lee Rodne.
“We are looking to address aortic stenosis, or narrowing, which is the most common valvular heart disease in developed countries. Traditionally aortic valves have been replaced with a bio-prosthetic or mechanical heart valve vs being surgically repaired, as surgeons haven’t had a tissue that can withstand such a high pressured area within the heart until now. CardioCel has been proven to have the tensile strength to work in a pressured environment, as well as having the added benefit of not calcifying like other tissues, and instead actively facilitates host tissue regeneration. This is a huge advantage for patients, as it means they can avoid the need to have repeat surgeries later in life.”
In addition to the presentation, Admedus will be hosting a 21st Century Innovators Dinner Meeting at EACTS on Monday, 5 October at 7.30pm featuring key opinion leaders Professor Bart Meuris and Domenico Mazzitelli from Munich, Germany. Admedus will be undertaking a CardioCel Tri-leaflet Aortic Valve Repair (CTRS) Clinical Study, which is expected to be initiated shortly at key global heart centres. This study is designed to further show the utility of CardioCel in repairing aortic heart valves and its potential for improved patient outcomes compared to bio-prosthetic valves which may need to be replaced multiple times throughout a patient’s life.
For the full EACTS programme, please visit http://www.eacts.org/annual-meeting/preliminary-programme/. Please see below for the 21st Century Innovators Dinner Meeting information.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 (0)8 9266 0100
Media:
Shevaun Cooper | PR Manager | Admedus Limited
Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com
Media Europe
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
admedus@fticonsulting.com
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com
About CardioCel®
CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue. CardioCel® is the Admedus Group’s lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group’s proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.
Help employers find you! Check out all the jobs and post your resume.
